Allergy Therapuetics - Public Comps and Valuation Multiples

Allergy Therapuetics Overview

About Allergy Therapuetics

Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).

Founded

2004

HQ

Employees

602

Website

allergytherapeutics.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $82.9M

LTM EBITDA -$32.9M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Allergy Therapuetics Financials

As of December 2025, Allergy Therapuetics reported last 12-month revenue of $82.9M and EBITDA of -$32.9M.

In the same period, Allergy Therapuetics generated $46.8M in LTM gross profit and -$50.2M in net income.

See Allergy Therapuetics valuation multiples based on analyst estimates

Allergy Therapuetics P&L

In the most recent fiscal year, Allergy Therapuetics reported revenue of $74.1M and EBITDA of -$38.1M.

Allergy Therapuetics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Allergy Therapuetics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$82.9M	XXX	$74.1M	XXX	XXX	XXX
Gross Profit	$46.8M	XXX	$39.4M	XXX	XXX	XXX
Gross Margin	56%	XXX	53%	XXX	XXX	XXX
EBITDA	-$32.9M	XXX	-$38.1M	XXX	XXX	XXX
EBITDA Margin	-40%	XXX	-51%	XXX	XXX	XXX
EBIT	-$38.6M	XXX	-$37.9M	XXX	XXX	XXX
EBIT Margin	-47%	XXX	-51%	XXX	XXX	XXX
Net Profit	-$50.2M	XXX	-$54.0M	XXX	XXX	XXX
Net Margin	-61%	XXX	-73%	XXX	XXX	XXX
Net Debt	XXX	XXX	$55.0M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Allergy Therapuetics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $82.9M. EBITDA for the last twelve months was -$32.9M. In the most recent fiscal year, Allergy Therapuetics achieved $74.1M in revenue and -$38.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$82.9M	Analyst estimates available to subscribers	$74.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$46.8M	Analyst estimates available to subscribers	$39.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	56.5% gross margin	Analyst estimates available to subscribers	53.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$32.9M	Analyst estimates available to subscribers	-$38.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-39.7% EBITDA margin	Analyst estimates available to subscribers	-51.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$38.6M	Analyst estimates available to subscribers	-$37.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-46.6% EBIT margin	Analyst estimates available to subscribers	-51.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$50.2M	Analyst estimates available to subscribers	-$54.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-60.6% net profit margin	Analyst estimates available to subscribers	-72.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$55.0M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Allergy Therapuetics

This financial data table provides comprehensive performance metrics for Allergy Therapuetics, a company based in United Kingdom of Great Britain and Northern Ireland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Allergy Therapuetics generated $82.9M in revenue over the last twelve months.
The company achieved -$32.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $46.8M.
Net income over the last twelve months reached -$50.2M.

Fiscal Year Performance

In the most recent fiscal year, Allergy Therapuetics reported $74.1M in total revenue.
Fiscal year EBITDA was -$38.1M.
The company maintained a gross profit margin of 53.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was -51.5%.
Net profit margin reached -72.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Allergy Therapuetics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Allergy Therapuetics Stock Performance

Allergy Therapuetics has current market cap of GBP 743M (or $1.0B), and EV of GBP 791M (or $1.1B).

Market Cap Evolution

Allergy Therapuetics Stock Data

As of January 16, 2026, Allergy Therapuetics's stock price is GBP 0 (or $0).

See Allergy Therapuetics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$1.0B	XXX	XXX	XXX	XXX	$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Allergy Therapuetics Valuation Multiples

Allergy Therapuetics's trades at 12.9x EV/Revenue multiple, and -29.9x EV/EBITDA.

See valuation multiples for Allergy Therapuetics and 15K+ public comps

Allergy Therapuetics Financial Valuation Multiples

As of January 16, 2026, Allergy Therapuetics has market cap of $1.0B and EV of $1.1B.

Equity research analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Allergy Therapuetics has a P/E ratio of -19.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$1.0B	XXX	$1.0B	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	12.8x	XXX	12.9x	XXX	XXX	XXX
EV/EBITDA	-32.3x	XXX	-29.9x	XXX	XXX	XXX
EV/EBIT	-27.5x	XXX	-27.7x	XXX	XXX	XXX
EV/Gross Profit	22.7x	XXX	n/a	XXX	XXX	XXX
P/E	-19.9x	XXX	-19.9x	XXX	XXX	XXX
EV/FCF	-24.4x	XXX	-25.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Allergy Therapuetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Allergy Therapuetics Margins & Growth Rates

Allergy Therapuetics's last 12 month revenue growth is 10%

Allergy Therapuetics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Allergy Therapuetics's rule of 40 is -43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Allergy Therapuetics's rule of X is -14% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Allergy Therapuetics and other 15K+ public comps

Allergy Therapuetics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	10%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-40%	XXX	-43%	XXX	XXX	XXX
EBITDA Growth	0%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-43%	XXX	-33%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-14%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	35%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	28%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	104%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial